Fulcrum Therapeutics

News

Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.

News

Company launched following $55 million series A funding round.

News

uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.